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Enhancing therapeutic activity against cancer cells and minimizing toxic effects on normal cells are critical
elements in chemotherapy. In this issue of Cancer Cell, Leite de Oliveira and colleagues reveal a previously
unrecognized role of a prolyl hydroxylase domain in promoting drug delivery to tumors and reducing toxicity
in normal organs.Chemotherapy using cytotoxic agents,
such as doxorubicin and cisplatin, to
damage cancer cells and inhibit tumor
growth remains a major therapeutic mo-
dality in cancer treatment. The low selec-
tivity of cytotoxic agents in killing cancer
cells over normal cells has been a major
challenge and significantly limits the
application of these drugs for cancer
treatment. This problem is further com-
pounded by the fact that tumors usually
have blood vessels that seem to be
leaky and tend to cause high interstitial
fluid pressure. This abnormal vasculature
limits drug delivery to cancer cells and,
therefore, reduces the effectiveness of
systemic chemotherapy (Carmeliet and
Jain, 2011; Heldin et al., 2004). In most
cases, the administration of higher drug
doses to increase drug concentrations in
tumor tissues is not a practical option
due to the risk of severe side effects.
Although local administration by injecting
cytotoxic agents into the tumor or the
main blood vessels feeding the tumor
may enhance anticancer activity and re-
duce systemic toxicity, such approaches
may only be applied to a small subset
of tumors at certain anatomic locations.
Clearly, new therapeutic approaches, in-
cluding novel strategies to normalize the
aberrant tumor vessels and developing
tumor-specific agents, are needed to im-
prove cancer treatment outcome.
Recent studies suggest that targeting
the prolyl hydroxylase domain-containing
protein 2 (PHD2) may lead to normaliza-
tion of blood vessels in tumors (Mazzone
et al., 2009) and prevent oxygen-induced
microvascular obliteration in the retina
(Duan et al., 2011) through HIF-depen-
dent mechanisms. Prolyl hydroxylases
are a family of enzymes that catalyze thehydroxylation of proline residues in a
variety of proteins and affect multiple
biological functions including collagen
formation, oxygen sensing, RNA tran-
scription, and NF-kB signaling (Gorres
and Raines, 2010). Among the prolyl hy-
droxylases, PHD2 seems to play a major
role in oxygen sensing and blood vessel
formation and significantly affects can-
cer oxygenation and metastasis. It was
recently shown that heterozygous dele-
tion of Phd2 in mice caused an increased
expression of HIF-1a and HIF-2a in endo-
thelial cells, leading to the transition of
endothelial tip cells to a more quiescent
stage and normalization of the endothelial
lining of tumor vasculatures (Mazzone
et al., 2009). The profound effect of
PHD2 on the structure of tumor blood
vessel provides the intriguing possibility
of targeting this molecule to normalize
blood flow in tumor tissues and to in-
crease drug delivery to cancer cells.
In this issue ofCancer Cell, Leite de Oli-
veira et al. (2012) report that reduced
PHD2 expression by heterozygous gene
deletion could significantly enhance the
therapeutic activity of doxorubicin and
cisplatin in mice and substantially reduce
the toxic side effects of the drugs in
normal organs, such as the heart and
kidneys. These striking effects seem to
be mediated by two separate mecha-
nisms, both linked to the activation of
hypoxia inducible factors (Figure 1). First,
the decrease in PHD2 activity caused a
significant increase in HIF-1a and HIF-2a
protein levels in endothelial cells, leading
to a normalization of the endothelial lining
of blood vessels within tumor tissues.
This, in turn, improved blood circulation
and reduced interstitial fluid pressure in
the tumor, resulting in an increase in theCancer Cell 22delivery of anticancer agents to the tumor.
The authors suggest that this mechanism
wasmainly mediated through the oxygen-
sensing function of PDH2 via HIF-2. In
contrast, the blood circulation in normal
organs seemed not to be affected by
heterozygous deletion of Phd2, and there
was no increase in drug concentrations
in the normal tissues. Importantly, Phd2
deficiency in normal cells led to HIF-
mediated upregulation of several key anti-
oxidant enzymes, including superoxide
dismutases, catalase, and glutathione
peroxidase-1, which enhanced the anti-
oxidant capacity of normal cells and
increased their ability to tolerate the
production of reactive oxygen species
(ROS) induced by anticancer drugs. The
authors showed that the protection of
normal organs by Phd2 heterozygous
deletion was likely due to activation of
the ROS-sensing mechanism of HIF-1
and HIF-2, which upregulate the expres-
sion of antioxidant enzymes.
The significant in vivo antitumor activity
of doxorubicin and cisplatin observed
in Phd2+/ mice suggests that targeting
PDH2 is a potentially promising strategy
to improve the overall therapeutic out-
come for cancer patients and that the
local drug concentrations in tumor tissues
may play a major role in determining
in vivo drug response. However, other
mechanisms, in addition to increased
local drug concentrations, could con-
tribute to the striking inhibition of tumor
growth by doxorubicin and cisplatin in
Phd2+/ mice. For instance, Phd2 dele-
tion might, through the activation of
HIF-1 and HIF-2, affect the energy me-
tabolism and redox regulation in tumor
stroma and, thus, potentially impair

























Figure 1. PHD2 Deficiency Increases the Therapeutic Activity of
Anticancer Agents and Decreases Side-Toxicity
In mice with wild-type Phd2, the blood vessels in tumor tissue have abnormal
endothelial lining, are leaky, and often cause high interstitial fluid pressure
(IFP), leading to a decrease in drug distribution to cancer cells (upper panel).
Heterozygous deletion of Phd2 promotes normalization of the tumor vascula-
ture and enhances drug delivery to cancer cells (lower panel). A decrease in
PHD2 activity also leads to elevated HIF-1a and HIF-2a, resulting in an upre-
gulation of antioxidant enzymes in normal tissue cells, thus, enhancing their
antioxidant capacity to detoxify ROS induced by anticancer agents.
PHD2, prolyl hydroxylase domain-2; HIF, hypoxia inducible factor; WT, wild-
type; AOC, antioxidant capacity; ROS, reactive oxygen species; EC, endothe-
lial cells; IFP, interstitial fluid pressure.
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gest that the tumor-stromal
cell interaction plays a major
role in affecting the ROS
status in cancer cells and
their drug sensitivity (Zhang
et al., 2012; Nakasone et al.,
2012). Thus, testing the po-
tential role of PHD2 in modu-
lating tumor-stroma interac-
tion would be an interesting
area of future investigation.
It is important to note that
the normalization of tumor
blood vasculature in Phd2+/
mice seem to be mediated,
at least in part, by the
HIF-driven upregulation of
VEGFR1 and VE-cadherin
(Mazzone et al., 2009). Thus,
suppression of the VEGF
pathway might potentially
have an opposite and per-
haps unfavorable effect. In-
deed, inhibition of angio-
genesis by blocking VEGF
using the humanized mono-
clonal antibody bevacizumab
has been shown to cause a
decrease in the delivery of
anticancer drugs to the tumor
tissues (Van der Veldt et al.,
2012). These observations to-
gether suggest that caution
should be exercised in con-
sidering combination of VEGF
blocking drugs and tradition-
al chemotherapeutic agents.
The proper timing of drug
administration would be im-
portant in avoiding potential
antagonist effect.
The two major conse-
quences of Phd2 deletion,
namely normalization of tu-
mor vasculature and en-hancement of antioxidant and detoxifica-
tion capacity in normal organs, suggest
that pharmacological inhibition of PHD2
may be an effective strategy to increase
the therapeutic activity and reduce the
toxic side-effect of traditional chemo-
therapeutic agents. However, systemic
administration of PHD2 inhibitors might
potentially cause an increase in HIF-1144 Cancer Cell 22, August 14, 2012 ª2012 Eand HIF-2 in cancer cells and, in turn, up-
regulation of detoxification enzymes and
drug resistance. However, the observa-
tion by Leite de Oliveira et al. (2012) that
silencing of Phd2 in tumor cells did not
significantly alter their expression of anti-
oxidant enzymes and drug response
seem to ease this potential concern,
although the mechanisms responsible forlsevier Inc.the major difference between
normal cells and cancer cells
in their response to PHD2
abrogation remain largely un-
clear. This is obviously an im-
portant area for future study.
Furthermore, since there are
multiple prolyl hydroxylases
that affect many important
biological functions, develop-
ment of specific inhibitors of
PHD2 is important for suc-
cessful pharmacological tar-
geting. In summary, the study
by Leite de Oliveira et al.
(2012) suggests that PHD2 is
a promising therapeutic target
and warrants further in vitro
and in vivo studies in terms
of mechanisms and clinical
applications.REFERENCES
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